dual agonist glp-1 glucagon The Emerging Role of and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction glp-1_analogs [TUSOM | Pharmwiki]

2008 Dec;43(6):1022-30

Regulatory systems cannot keep pace with the AI assisted evolution of peptide science

Electron microscopic analysis has shown that 48 h after LPS treatment, the glycocalyx of glomerular endothelial cells and podocytes begins to disappear, and endothelial fenestrations are lost or edematous, such that a gap forms between the podocytes and the basement membrane (15)

Beyond Month 6: Maintenance Most patients continue at 2.4 milligrams weekly through month 12, when full clinical trial endpoints are typically reached

Bray GP, Harrison PM, OGrady JG, Tredger JM, Williams R: Long-term anticonvusant therapy worsens outcome in paracetamol-induced fulminant hepatic failure

Peptide drugs that target local inflammation and angiogenesis demonstrate reduced lesion size in animal models and early human safety data